Want the short version?
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Kathleen Goin is Chief Operating Officer at Palvella Therapeutics. OQRO lists 7 transactions filed with the SEC under this name, the latest on Oct 23, 2026, each linked to the official Form 4.
Chief Operating Officer
Disclosures on record
7
Companies involved
1
Palvella TherapeuticsPVLA
7 disclosures · Oct 2026 · 3 sold
Oct 21, 2026Sold~$253Kdisclosed Oct 23
DetailsOfficial recordOct 21, 2026Sold~$208Kdisclosed Oct 23
DetailsOct 21, 2026Sold~$77Kdisclosed Oct 23
DetailsOfficial recordOct 21, 20262,148disclosed Oct 23
DetailsOfficial recordOct 21, 20262,165disclosed Oct 23
DetailsOfficial recordOct 21, 20262,165disclosed Oct 23
DetailsOfficial recordOct 21, 20262,148disclosed Oct 23
DetailsOfficial recordKathleen Goin has no open-market purchase on record since 2026. Sales in 1 of the 1 years since 2026.
Kathleen Goin reported 0 open-market purchases and 3 sales since 2026; no open-market purchase.
| Year | Bought | Sold |
|---|---|---|
| 2026 | — | $537K3×3 trades |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Kathleen Goin has no open-market purchase on record since 2026. Sales in 1 of the 1 years since 2026.
In SEC filings since 2026: no open-market purchase is on record; the latest open-market sale is from 2026.
Palvella Therapeutics (PVLA), from 2026 to 2026: 0 purchases and 3 sales.
Kathleen Goin reported 0 open-market purchases and 3 sales here, 2026.
Closing prices and the companies' last annual figures; a − or + is a fact of the close, not a forecast.